About US
Contact us
-
FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer populationIn a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to expand Talzenna into a broader prostate cancer population has failed to impres2025/5/22
-
AstraZeneca, Merck duke it out at the top of oncologists’ pharma perception rankingAstraZeneca and Merck are still leading the pack when it comes to how oncologists perceive makers of cancer drugs, according to a new report from ZoomRx. Though Merck edged out AstraZeneca by a singl2025/5/22
-
SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccineSome five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer. The win frees up the company to export its shot—which protects against 132025/5/20
-
After WHO loses its top donor in US, Novo Nordisk Foundation and China step up with large contributionsWith the withdrawal of the U.S. from the World Health Organization (WHO), the United Nations-backed agency has lost its topdonor. Helping compensate for the funding shortfall is the Novo Nordisk Foun2025/5/20
-
Merck's Keytruda finds a path in ovarian cancer with phase 3 win in certain recurrent patientsMerck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain patients, th2025/5/16
-
Riding its Peloton buyout, Merck rolls to third FDA nod for potential blockbuster WeliregSix years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal. On Wednesday, the FDAapproveda third indication for Welir2025/5/13
-
AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC EmrelisAfter flexing its antibody-drug conjugate bona fides at last year’s American Society of Clinical Oncology (ASCO) conference, AbbVie is advancing its solid tumor ambitions with a new FDA green light.2025/5/13
-
Apellis' weak quarter for Syfovre signals uphill climb for geographic atrophy med: analystDespite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic atrophy market is a tough nut to crack. Syfovre—which became the first2025/5/8
-
As Bayer's restructuring rolls on, Kerendia and Nubeqa power pharma unit to surprising sales increaseThanks to hefty salesincreasesfrom kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma division weathered the storm from the loss of exclusivity in the U.S. of blockbust2025/5/8
-
Roche spotlights Perjeta's staying power with 10-year breast cancer survival resultsRoche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast cancer. Now, the company can further back up the regimen’s prowess with a2025/5/6